Dongcheng Pharmaceuticals intends to acquire andyco plus code nuclear medicine

Dongcheng Pharmaceuticals announced the restructuring plan on the morning of the 12th, the company intends to pay cash and issue shares to buy 100% of Andico shares and raise matching funds. Andico's 100% stake is priced at 160 million yuan, and the company intends to raise matching funds by issuing shares to no more than 10 specific investors, raising no more than 743 million yuan.
According to the announcement, Andico was established in 2006, is one of the two domestic companies with 18F-FDG drug approval number, mainly engaged in 18F-FDG research and development, production and sales, as well as for hospitals to provide the integrated services of the supply of positive electronic drugs. At present, Andico's main product 18F-FDG, is widely used in PET-CT spectral diagnosis, can early detection of systemic tumor lesions, accurately judge its good, malignant, so as to correctly guide clinical treatment decision-making. Through the acquisition of Andico, the company will complete the full coverage of single photon drugs and positive electronic drugs, diagnostic drugs and therapeutic drugs, become a complete provider of nuclein drugs and nuclear medicine solutions, will greatly enhance the company's core competitiveness and overall strength in the field of nuclear medicine, greatly consolidate the company's position in the field of nuclear medicine industry.
according to the performance commitment, Andico's audited consolidated statements for 2017, 2018 and 2019, net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses, were not less than 78 million yuan, 95 million yuan and 117.5 million yuan, respectively.
company's shares will not be traded for the time being. (China Securities Network)